ImmunityBio, Inc. (NASDAQ: IBRX) recently announced that its innovative drug Anktiva® has officially entered the Saudi Arabian market, offering new treatment options for local patients with bladder cancer and lung cancer.

It is worth noting that the entire process, from reaching agreements with Middle Eastern partners to obtaining market access, took less than two months, demonstrating highly efficient commercial execution. This breakthrough marks an important milestone in ImmunityBio's strategic layout in the Middle Eastern market. As the company's core immunotherapy product, Anktiva®'s rapid entry into Saudi Arabia's healthcare system will not only benefit local patients but also lay a solid foundation for subsequent expansion into other Gulf countries.